Vir Biotechnology Inc (VIR)
Working capital turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 74,205 | 86,180 | 1,580,470 | 1,087,070 | 76,368 |
Total current assets | US$ in thousands | 1,042,460 | 1,588,230 | 2,519,080 | 1,562,820 | 772,365 |
Total current liabilities | US$ in thousands | 119,662 | 175,407 | 511,029 | 341,242 | 99,064 |
Working capital turnover | 0.08 | 0.06 | 0.79 | 0.89 | 0.11 |
December 31, 2024 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $74,205K ÷ ($1,042,460K – $119,662K)
= 0.08
The working capital turnover of Vir Biotechnology Inc has displayed fluctuations over the years. In 2020, the company had a working capital turnover of 0.11, which improved significantly to 0.89 in 2021, indicating a more efficient use of working capital to generate revenue. However, this ratio decreased slightly to 0.79 in 2022, suggesting a slight dip in efficiency. Subsequently, in 2023, the working capital turnover dropped to 0.06, signifying a significant decline in the company's ability to utilize its working capital effectively. The ratio improved marginally to 0.08 in 2024, but it remains relatively low compared to the previous years. This trend indicates some variability in Vir Biotechnology's ability to convert its working capital into sales over the years, highlighting the importance of monitoring and managing working capital efficiently.
Peer comparison
Dec 31, 2024